Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR180711C in Mild Alzheimer's Disease
NCT00602680Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jan 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSR180711C in Alzheimer's disease (AD) (5 arms), sponsored by Sanofi. Primary endpoint: Change in cognitive performance at 4 weeks. Started Jan 2008; status: terminated.
02
Drugs
SSR180711C
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00602680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602680.